Human Beta-defensin 1 in Vitiligo

Not Applicable

• Conditions: Vitiligo
• Interventions: Other: skin biopsy before and after NB-UVB phototherapy

• Registration Number: NCT03832751
• Lead Sponsor: Cairo University

Brief Summary

There is a need to know the role of human beta defensin-1 in vitiligo pathogenesis and the probability of finding newer and effective therapy for vitiligo in the future.

Detailed Description

Not available

Study Timeline

• Status Verified: 2019-02
• Study First Submitted: 2019-02-05
• Study First Submitted QC: 2019-02-05
• Last Update Submitted: 2019-02-05
• Study First Posted: 2019-02-06
• Last Update Posted: 2019-02-06
• Study Start: 2019-03
• Primary Completion: 2019-12
• Study Completion: 2019-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• Patients with non-segmental vitiligo.
• Both genders.
• Age more than 18 years old.
• New cases or cases not receiving any treatment for at least 3 months prior to the study.

Exclusion Criteria

• Universal or segmental vitiligo.
• Any contraindication to phototherapy treatment.
• History of autoimmune diseases or other systemic diseases.
• Any other skin disease.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Healthy controls	skin biopsy before and after NB-UVB phototherapy	Tissue levels of human beta-defensin 1 in healthy controls
vitiligo patients	skin biopsy before and after NB-UVB phototherapy	Tissue levels of human beta-defensin 1 in vitiligo patients before and after NB-UVB phototherapy

Primary Outcome Measures

Name	Time	Method
Tissue levels of human beta-defensin 1 before and after NB-UVB phototherapy	6 months to 1 year